ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma

ClinicalTrials.gov ID: NCT03126019

Public ClinicalTrials.gov record NCT03126019. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 12:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Study identification

NCT ID
NCT03126019
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Incyte Corporation
Industry
Enrollment
126 participants

Conditions and interventions

Conditions

Interventions

  • Parsaclisib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 13, 2018
Primary completion
Feb 25, 2021
Completion
Jun 6, 2024
Last update posted
Mar 13, 2025

2018 – 2024

United States locations

U.S. sites
22
U.S. states
17
U.S. cities
21
Facility City State ZIP Site status
Arizona Oncology Associates - Biltmore Cancer Center Phoenix Arizona 85016
Beverly Hills Cancer Center Beverly Hills California 90211
Synergy Hematology and Oncology Medical Associates Los Angeles California 90036
St. Joseph Heritage Healthcare Santa Rosa California 95403
American Institute of Research Corporate Office Whittier California 90603
Cancer Center of Central Connecticut Southington Connecticut 06489
Florida Cancer Specialists & Research Institute Fort Myers Florida 33901
Asclepes Research Centers Spring Hill Florida 34606
Clinical Trials of Swla Llc Lake Charles Louisiana 70601
Saint Agnes Hospital Baltimore Maryland 21229
Barbara Ann Karmanos Cancer Hospital Detroit Michigan 48201
Hattiesburg Clinic Hematology Hattiesburg Mississippi 39401
Saint Luke'S Hospital Kansas City Missouri 64111
Sarah Cannon Research Institute Kansas City Missouri 64132
Clinical Research Alliance, Inc. New Hyde Park New York 11042
Duke University Medical Center Durham North Carolina 27710
Gabrail Cancer Center Canton Ohio 44718
University of Pennsylvania Health System Philadelphia Pennsylvania 19104
Charleston Hematology Oncology Associates Pa Charleston South Carolina 29414
Tennessee Oncology Nashville Tennessee 37203
Renovatio Clinical Consultants Llc Spring Texas 77380
University of Washington Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 61 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03126019, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 13, 2025 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03126019 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →